Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly D
13 Mars 2008 - 12:01PM
PR Newswire (US)
-- Trial results of combination therapy VELCADE, melphalan and
prednisone reported a 32 percent complete remission rate with 85
percent of patients alive at three years -- CAMBRIDGE, Mass., March
13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc.
(NASDAQ:MLNM) today announced the publication of updated results of
the Phase I/II clinical trial of the combination therapy VELCADE,
melphalan and prednisone (VcMP) in newly diagnosed multiple myeloma
patients, who were ineligible for stem cell transplantation.
Results of this study included one of the highest reported complete
remission (CR) rates, which is an important indicator for long-term
survival, and the highest three- year survival rate reported in the
non-transplant setting. These results provided the basis for the
Phase III VISTA trial. The Company submitted a supplemental New
Drug Application (sNDA) to the U.S. Food and Drug Administration
(FDA) in December 2007 for VELCADE expansion into newly diagnosed
multiple myeloma. The FDA decision date for the sNDA is scheduled
for June 20, 2008. The Company's co-development partner, Johnson
& Johnson Pharmaceutical Research & Development, L.L.C.
(J&JPRD) also has filed a corresponding application with the
European Medicines Evaluation Agency. (Logo:
http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) "These
results support the strong relationship between high rates of
durable complete remissions with long-term survival in patients
with newly diagnosed multiple myeloma," said Nancy Simonian, M.D.,
Chief Medical Officer, Millennium. "We are confident that VELCADE
will be a key component of the standard of care in this patient
setting." The study was pre-published online in the journal,
Haematologica. Data from the 60 patient Phase I/II trial conducted
by the PETHEMA Foundation in Spain were evaluated by the stringent
European Group for Blood and Marrow Transplantation (EBMT) criteria
and results are as follows: -- Results showed an
immunofixation-negative CR rate of 32 percent and an overall
response rate (ORR) of 89 percent with VcMP. -- The overall
survival rate at 38 months was 85 percent with VcMP compared to the
38 percent historical control with melphalan and prednisone (MP)
(p/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and
neutropenia (3%). A total of 50% of patients experienced serious
adverse events (SAEs) during the studies. The most commonly
reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%),
vomiting (4%), and nausea, dehydration, dyspnea and
thrombocytopenia (each 3%). Adverse events thought by the
investigator to be drug-related and leading to discontinuation
occurred in 22% of patients. The reasons for discontinuation
included peripheral neuropathy (8%), asthenic conditions (3%) and
thrombocytopenia and diarrhea (each 2%). In total, 2% of the
patients died and the cause of death was considered by the
investigator to be possibly related to study drug: including
reports of cardiac arrest, congestive heart failure, respiratory
failure, renal failure, pneumonia and sepsis. This integrated
analysis does not include the Phase III, VELCADE plus DOXIL study.
For more information about VELCADE clinical trials, patients and
physicians can contact the Millennium Medical Product Information
Department at 1-866-VELCADE (1-866-835-2233). About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical
company based in Cambridge, Mass., markets VELCADE, a novel cancer
product, and has a robust clinical development pipeline of product
candidates. Millennium's research, development and
commercialization activities are focused in two therapeutic areas:
oncology and inflammation. By applying its knowledge of the human
genome, understanding of disease mechanisms and industrialized drug
discovery platform, Millennium is developing an exciting pipeline
of innovative product candidates. Millennium's website is
http://www.millennium.com/. This press release contains
"forward-looking statements," including statements about the
Company's growth and development of products. Various important
risks may cause the Company's actual results to differ materially
from the results indicated by these forward-looking statements,
including: adverse results in its drug discovery and clinical
development programs; failure to obtain patent protection for its
discoveries; commercial limitations imposed by patents owned or
controlled by third parties; the Company's dependence upon
strategic alliance partners to develop and commercialize products
and services based on its work; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from
its development efforts; product withdrawals; competitive factors;
difficulties or delays in manufacturing the Company's products;
government and third-party reimbursement rates; the commercial
success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection;
achieving revenue consistent with internal forecasts; and the
requirement for substantial funding to conduct research and
development and to expand commercialization activities. For a
further list and description of the risks and uncertainties the
Company faces, see the reports it has filed with the Securities and
Exchange Commission. The Company disclaims any intention or
obligation to update or revise any forward- looking statements,
whether as a result of new information, future events or otherwise.
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com/
Contacts: Jennifer Snyder (media) Kyle Kuvalanka (investors) (617)
444-1439 (617) 761-4734
http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
http://photoarchive.ap.org/ DATASOURCE: Millennium Pharmaceuticals,
Inc. CONTACT: Media: Jennifer Snyder, +1-617-444-1439; Investors:
Kyle Kuvalanka, +1-617-761-4734, both for Millennium
Pharmaceuticals, Inc. Web site: http://www.millennium.com/ Company
News On-Call: http://www.prnewswire.com/comp/114562.html
Copyright
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024